Effects of pentoxifylline and nabumetone on the serum levels of IL-1β and TNFα in rats with adjuvant arthritis

Inflammation Research

Volumn 49, Issue 1, 2000, Pages 14-19

  Silva, J C R ^a   Rocha, M F G ^a   Lima, A A M ^a   Brito, G A C ^a   De Menezes, D B ^a   Rao, V S N ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Adjuvant arthritis; ELISA (enzyme linked immunosorbent assay); Nabumetone; Pentoxifylline; Serum IL 1 and TNF

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; FREUND ADJUVANT; INTERLEUKIN 1BETA; NABUMETONE; PENTOXIFYLLINE; PHOSPHODIESTERASE IV INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; NONHUMAN; PAW EDEMA; PLETHYSMOGRAPHY; RAT;

EID: 0033983616     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000198     Document Type: Article

References (30)

1. [1] Smith WL, DeWitt DL. Biochemistry of prostaglandin endoper-oxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995; 15: 179-94.
2. [2] Mitchell JA. Cyclooxygenase-2 as a therapeutic target. Inflamm Res 1997; 46: (Suppl 3) S 183.
3. [3] Sano H, Hla T, Maier JA, Crofford LJ, Case JP, Maciag T, Wilder RL. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992; 89: 97-108.
4. [4] Crofford LJ, Wilder RL, Ristimäki AP, Sano H, Remmers EF, Epps HR, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. J Clin Invest 1994; 93: 1095-101.
5. [5] Mertz PM, DeWitt DL, Stetler-Stevenson WG, Wahl LM. Interleukin-10 suppression of monocyte prostaglandin synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. J Biol Chem 1994; 269: 21322-9.
6. [6] Akarasereenont P, Mitchell JA, Bakhle YS, Thiemermann C, Vane JR. Comparison of the induction of cyclooxygenase and nitric oxide synthase by endotoxin in endothelial cells and macrophages. Eur J Pharmacol 1995; 273: 212-8.
7. [7] Arias-Negrete S, Keller K, Chadee K. Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages. Biochem Biophys Res Commun 1995; 208: 582-9.
8. [8] Ford-Hutchinson AW. New highly selective cyclooxyganse-2 inhibitors. In: Bazan C, Botting J, Vane J, editors. New targets in inflammation. Inhibitors of COX-2 or Adhesion molecules. Dordrecht: Kluwer Adademic Publisher, 1996; 55-62.
9. [9] Wallace JL, Bak A, McKnight W, Asfaha S, Sharkey KA, MacNaughton NK. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: Implication for gastrointestinal toxicity. Gastroenterology 1998; 115: 101-9.
10. [10] Camussi G, Lupia E. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs 1998; 55: 613-20.
11. [11] Issekutz AC, Meager A, Otterness I, Issekutz TB. The role of tumor necrosis factor-alpha and IL-1 in polymorphonuclear leukocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis. Clin Exp Immunol 1994; 97: 26-32.
12. [12] Barrera P, Boerbooms AM, van de Putte LB, van der Meer JW. Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum 1996; 25: 234-53.
13. [13] Juan-Manuel A, Espinoza LR. Phosphodiesterase inhibitor pentoxifylline: an anti-inflammatory/immunomodulatory drug potentially in some rheumatic diseases. J Rheumatol 1995; 22: 595-9.
14. [14] Bessler H, Gilgal R, Djaldetti M, Zahavi I. Effect of pentoxifylline on the phagocytic activity, cAMP levels and superoxide anion production by monocytes and polymorphonuclear cells. J Leukoc Biol 1986; 40: 747-54.
15. [15] Roger A. The role of IL-10 in the inhibition of LPS-mediated TNFα release from human PMBCs by phosphodiesterase 4 (PDE4) inhibitors. Inflamm Res 1997; 46 (Suppl 3): S218.
16. [16] Smith-Oliver T, Noel LS, Stimpson SA, Yarnall DP, Connolly KM. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 1993; 5: 298-304.
17. [17] Crofford LJ, Wilder RL. Arthritis and Autoimmunity in Animals. In: McCarty DJ, Koopman WJ, editors. Arthritis and Allied Conditions/A Textbook of Rheumatology. Pennsylvania: Lea & Febiger, 1993: 525-39.
18. [18] Kerwar SS, Oronsky AL. Methotrexate in rheumatoid arthritis: studies with animal models. Adv Enzyme Regul 1989; 29: 247-65.
19. [19] Newbold BB. Chemotherapy of arthritis induced in rats by injection of mycobacterial adjuvant. Br J Pharmacol 1963; 21: 127-36.
20. [20] Pearson CM. Development of arthritis, periarthritis, and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 1956; 91: 95-101.
21. [21] Demir S, Inal-Erden M. Pentoxifylline and N-acetylcysteine in hepatic ischemia/reperfusion injury. Clin Chem Acta 1998; 275: 127-35.
22. [22] Cardin S, Soll AH, Tache Y. Different effects of indomethacin and nabumetone on prostaglandin-mediated gastric responses to central vagal activation in rats. J Pharmacol Exp Ther 1995; 275: 667-73.
23. [23] McComb J, Gould T, Chlipala E, Sennello G, Frazier J, Kieft G, et al. Antiarthritic activity of soluble tumor necrosis factor receptor type 1 forms in adjuvant arthritis: correlation of plasma levels with efficacy. J Rheumatol 1999; 26: 1347-51.
24. [24] Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animals models of arthritis - comparison of efficacy in animals models with human clinical data. Arthritis Rheumatism 1999; 42: 498-506.
25. [25] Lupia E, Montrucchio G, Battaglia E, Modena V, Camussi G. Role of tumor necrosis factor-α and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. Eur J Immunol 1996; 26: 1690-4.
26. [26] Dayer JM, Beutler B, Cerami A. Chachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162: 2163-8.
27. [27] Philippe L, Gegout-Pottie P, Guingamp C, Bordji K, Terlain B, Netter P, et al. Relations between functional, inflammatory, and degenerative parameters during adjuvant arthritis in rats. Am J Physiol 1997; 273: R1550-6.
28. [28] Coran AG, Drongowski RA, Paik JJ, Remick DG. Ibuprofen intervention in canine septic shock: reduction of pathophysiology without decreased cytokines. J Surg Res 1992; 53: 272-9.
29. [29] Johnson RW, von Borell E. Lipopolysaccharide-induced sickness behavior in pigs is inhibited by pretreatment with indomethacin. J Anim Sci 1994; 72: 309-14.
30. [30] Nowak D, Lewandowicz J, Dbkowska B, Marczak J. Combination of methotrexate and prednizone decreases circulating concentration of interleukin 1 beta and interleukin 6 in patients with rheumatoid arthritis. Poor correlation of cytokine suppression with clinical improvement. Int J Immunopathol Pharmacol 1999; 12: 13-21.